ALPN News and Press, Alpine Immune Sciences Inc. From 11/14/22

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30...

Alpine Immune Sciences ( NASDAQ: ALPN ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is $18.68M. Over the last 3 months, EPS estimates have seen 3 up...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, a...

- ALPN-303 dose-dependently reduces serum galactose-deficient IgA1 (Gd-IgA1), a pivotal molecule implicated in the pathogenesis of IgA nephropathy (IgAN) - - Data further supports best-in-class profile and initiation of glomerulonephritis (GN) basket clinical trial...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for ALPN-303’s phase 1 study (RUBY-1) at the upcoming American ...

Summary The recent termination of ALPN-202 trials due to another patient's death caused the share price to plummet. While this was anticipated, I believe that the market has overreacted due to several reasons. The company has enough cash runway to guide them to 2025. ALPN-...

Summary The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits. Next year, Alpine is poised to run basket studies on ALPN303 which can move...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303 's phase 1 study (RUBY-1) at upcoming scientific conferenc...

Alpine Immune Sciences ( NASDAQ: ALPN ) shed ~9% pre-market Monday after the immunotherapy company announced that it decided to end enrollments in trials for cancer candidate davoceticept (ALPN-202) after a study subject died. Alpine ( ALPN ) was advancing davoceti...

- Company’s primary focus will be the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innova...